


Global Engage 

MICROBIOME FUTURES

GLOBAL TRANSLATIONAL ROADMAP



NEW YORK • May 23RD 2018





Microbiome Futures was born with the goal to provide the microbiome translational community with a unique opportunity to come together and collectively assess the state of affairs in the space.

Great expectations have been raised over the last two decades by advances made in unlocking the mysteries of the microbiome and by first inroads taken into harnessing the resulting scientific insights for wellness and therapeutic purposes.

The sobering reality however is that the development of microbiome based therapeutics and wellness products has been slow in the making because of our limited understanding of the complex biology underlying the microbiome's function and physiology.

Despite this knowledge gap however, researchers, investors and companies are increasingly coming together to devise new and creative ways in which to address the challenge.

In the microbiome space today, many strategic and investment decisions are made early in the value chain and include interdisciplinary and multi-directional collaboration to support existing and future investments in the space.

Attending this Summit will provide you with a unique opportunity to contribute to the discussions and to mix and interact with scientific experts, CEOs, CSOs and investors in the microbiome space.

Don't miss this one-time opportunity to help shape the future of microbiome translation.

CONGRESS SYNOPSIS

Microbiome Futures is a landmark forum that will document the future of microbiome research and commercialisation.

The live event will be the culmination of a thorough research process, during which the working group will be gathering input from a global pool of stakeholders in the microbiome space.

Combining the summary and analysis of the roundtable discussion, the working group's feedback, and the KOLs' input, it will be published as the Roadmap for Microbiome Translation in Nature Biotechnology.

Talking points will cover:

- Moving from correlation to causation
- Models of disease and healthy status to guide the path from preclinical to clinical studies
- Using native versus engineered strategies
- Balancing a DNA level approach with a vertical integration of information, in order to maximize the therapeutic or prophylactic predictability of outcomes
- Developing consortia versus more reductionist single organism-based approaches
- Identifying single molecule interventions that match existing drug development and regulatory frameworks
- Developing robust organism-based solutions

CONGRESS SCHEDULE

May 22nd 2018

19:00 Drinks Reception & Gala Dinner

May 23rd 2018

7:30 Breakfast & Registration

9:00 Introductions & Opening Remarks

9:45 Break

10:00 Panel Discussion

12:30 Closing Summary & Next Steps

..... **Silver Sponsor**



..... **Gala Dinner Sponsor**



..... **Bag Sponsor**



..... **Lanyard Sponsor**



..... **Other Sponsors & Supporters**





DENISE KELLY
VENTURE PARTNER, SEVENTURE PARTNERS

Denise joined Seventure in September 2015 as an Investment Advisor to the Life Sciences Team. Her focus is in Human Microbiome Research and her time is dedicated to providing global coverage of the Life Science community and in prospecting new investment opportunities on behalf of Seventure. Prior to joining Seventure, Denise was Head of her Research team at the World-renowned Rowett Institute, University of Aberdeen, Scotland where she acquired over 20 years' experience in gut microbiology and immunology. She was the (former) Founder Director, CEO and CSO of GT Biologics Ltd, one of the first translational spinouts, developing Innovative Microbiome-based Therapies. She is the main inventor on numerous EU and USA patent applications and during her career has collaborated with pharmaceutical and healthcare companies on several translational projects.



DIRK GEVERS
GLOBAL HEAD, JANSSEN HUMAN
MICROBIOME INSTITUTE

As the Global Head of the Janssen Human Microbiome Institute (JHMI), Dirk deepens the Janssen R&D's leadership, scientific understanding and capabilities in this emerging and exploding area of science. Dirk joined from his most recent role as Senior Group Leader of Microbial Systems and Communities at the Broad Institute of MIT and Harvard. In this position, Dirk served as a scientific liaison between different organizational components, including the Broad Institute's data generation platforms and both clinical and analytical collaborators on a number of microbiome-related projects. Dirk's research efforts at the Broad Institute included the characterization of the microbial imbalance associated with diseases such as Crohn's disease, type 1 diabetes and colorectal cancer. He was also involved with the National Institutes of Health (NIH) Human Microbiome Project (HMP), holding a leading role in the Data Analysis Working Group, consisting of over 50 investigators focused on human microbiome research.



ARPITA MAITI
 SENIOR DIRECTOR, EXTERNAL
 SCIENCE & INNOVATION, PFIZER

As Senior Director, External Science & Innovation (ES&I), Arpita is a member of the external opportunities (discovery to Proof of Concept) search and evaluation team for Inflammation & Immunology, at Pfizer. She also leads strategy and partnering efforts in the microbiome for Pfizer. ES&I is an externally-focused scientific team of PhDs/MDs embedded within Pfizer research groups and seeks to identify late-breaking science that forms the basis of innovative therapies and drives related collaborations that deliver value to Pfizer, its partners, and patients. Prior to joining Pfizer, Arpita was Associate Director of R&D Alliance Design & Management at Vertex Pharmaceuticals, Inc. In this role, she designed new alliance paradigms to drive innovation in R&D and managed a team responsible for the oversight of external research projects with strategic research partners.



BERNAT OLLE
 CEO, VENDANTA BIOSCIENCES

Dr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of several companies of the PureTech Health portfolio and served as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences. In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards, and in 2015 he was awarded the Princess of Girona business award by the King of Spain. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, Spain, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.



RICHARD BONNEAU
DIRECTOR, NYU CENTER FOR DATA SCIENCE

Dr. Bonneau is Group Leader for Systems Biology at the newly founded Flatiron Institute in New York City and Director of the New York University Center for Data Science. His group works on inferring and modeling both biological and social networks, developing new methods to learn very large networks from large collections of genomics data. They actively participate in applying these methods to ongoing systems biology consortia efforts that span bacteria, model systems, bacteria, the immune system and crop plants. His group also develops methods for the prediction and design of bio molecular polymers (and polymers that mimic biological structure). Dr. Bonneau is a founding member of the Rosetta commons and a member of the RosettaCommons executive board. He is committed to doing all he can to leverage his position to help increase diversity in the many computational fields that comprise the field of data science.



DUNCAN PEYTON
CHIEF EXECUTIVE OFFICER,
4D PHARMA PLC

Duncan has a proven track record in identifying, investing and growing business within the pharmaceutical sector. He was the founder of Aquarius Equity, a specialist investor in businesses within the life science sector, which provided investors' access to innovative, high growth potential companies that delivered significant capital growth. Duncan started his career in a bio-science start-up business, which ultimately went on to list on the London Stock Exchange, subsequently qualified as a corporate finance lawyer with Addleshaw Goddard, and later joined 3i plc as an investment manager. Duncan founded Aquarius in 2005, which made founding investments into Nanoco Technologies Ltd, Auralis Limited (subsequently sold to ViroPharma), Tissue Regenix Group plc, C4X Discovery plc and Brabant Pharma (subsequently sold to Zogenix). In 2014 Duncan founded 4D pharma plc which focuses on the microbiome from both a therapeutic and diagnostic perspective. With research teams based both in US and Europe, and manufacturing based in Spain, 4D pharma has developed an end to end capability focussing on fields such as cancer, inflammation and respiratory. 4D currently has 17 programmes across these areas of interest, from discovery to phase II.



ELODIE GHEDIN
DIRECTOR, NYU CENTER FOR GENOMICS
AND SYSTEM BIOLOGY

Elodie Ghedin joined the NYU faculty in April 2014, following 8 years at the University of Pittsburgh School of Medicine. She was named a MacArthur Foundation Fellow (2011), A Kavli Frontier of Science Fellow (2012), and an American Academy of Microbiology Fellow (2017). Her laboratory uses comparative genomics, evolutionary biology, and systems biology techniques to generate critical insight about host-pathogen interactions. Professor Ghedin studies microbial and viral population structures, and how these impact host response to infection and emerging infectious diseases. Her research focuses on characterizing influenza virus diversity within and across infected hosts, and the interactions of microbes (bacterial, fungal, and viral) in the respiratory tract, to better understand the dynamics of viral transmission.



MODERATOR

**GASPAR
TARONCHER-OLDENBURG**

Gaspar is Consultant-in-Residence for Global Engage. Previously, Gaspar was Founding and Managing Editor of Nature’s SciBX: Science-Business eXchange (now BioCentury Innovations), a joint publication with BioCentury. SciBX bridged the translational divide by providing in-depth analysis of the scientific, clinical and commercial context for the latest discoveries in the life sciences. Before launching SciBX in 2008, Gaspar was a scientific editor of Nature Biotechnology for five years. Prior to joining Nature Biotechnology, Gaspar conducted research and taught at Princeton University, MIT and Tufts University.



MODERATOR

SUSAN JONES

Susan is Senior Research Editor at Nature Biotechnology and is based in Cambridge, UK. Susan is the lead microbiology editor for the journal, with special emphasis on all microbiome research. Prior to joining NBT in 2012, Susan spent three years as a Senior Research Editor at PLOS Medicine, and before that, she was part of the Nature Reviews Microbiology team, where she rose to the position of Chief Editor in 2008. Before joining Nature Reviews Microbiology in 2003, Susan did postdoctoral work at Imperial College London, UK, and Warwick University, UK investigating transcriptional mechanisms underlying stress and virulence in bacteria.

GALA DINNER

AFTER-DINNER SPEAKER



DAN R. LITTMAN
PROFESSOR, NYU

Join us the evening before the live panel on May 22nd for a networking dinner with the panel and distinguished guests.

Hosted in the beautiful library of the New York Academy of Medicine, dinner includes a drinks reception with hors d’oeuvres and a full 3-course sit-down dinner with your peers.

We are also pleased to be welcoming Dan R. Littman from NYU as our after-dinner speaker.





NEW YORK ACADEMY OF MEDICINE

1216 5th Avenue
New York, NY 10029

Established in 1847, The New York Academy of Medicine aims to address the health challenges facing the world's rapidly growing urban populations. It is home to one of the most significant historical libraries in medicine and public health in the world.

Located in a historic Fifth Avenue building on Museum Mile, the New York Academy of Medicine is the ideal venue to come together with your peers to decide on the future of microbiome.

www.nyam.org

